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Background: DAPT is mandatory in PCI patients but interindividual variability in platelet response has been reported. The highly polymorphic 
cytochrome (CYP) P450 system of the liver plays a key role in clopidogrel metabolism, with the loss-of-function allele CYP2C19*2 being associated 
with a blunted antiplatelet response to clopidogrel. High on-treatment platelet reactivity (HTPR) is associated with an increased risk of adverse 
events after PCI, with this risk specifically linked with the presence of the loss-of-function allele CYP2C19*2.Optimization of platelet inhibition in 
patients with HTPR by increasing clopidogrel or, alternatively, by new more potent P2Y12 inhibitors is a controversial issue. We sought to investigate 
the antiplatelet effect in terms of level platelet reactivity (< 450 Area under the curve(AU*min)) of standard dose of prasugrel(10 mg/day) versus 
high dose clopidogrel (150 mg/day) in patients undergoing PCI with HTPR (primary end-point)and the correlation of genotype variation (loss-of-
function allele CYP2C19*2)with basaline platelet reactivity and after either double dose of clopidogrel and prasugrel. Secondary end-points were 
MACCE, stent thrombosis and bleedings in overall population at 30 days,6 and 12 months follow-up.
Methods: In this prospective, randomized, cross-over study consecutive patients undergoing PCI with stent implantation has been considered for 
PR with Multiplate assessment at 72 h after the procedure. 80 patients with HTPR (defined as area under curve-AUC >450 or >45 Unit) are included 
into the study and their genotyping has been performed for variation in loss-of-function CYP2C19*2 allele in homo or heterozygotes arrangement.50 
patients HTPR are randomized (Day 0) in a 1:1 ratio to either clopidogrel 150 mg a day, or prasugrel 10 mg a day, until Day 14 post randomization. 
At 14 ± 2 day PR measurement and safety evaluation has been performed (with blood sample obtained 16-18 hours after the last study-drug dose) 
followed by crossover to the switched therapy for an additional 14 days. At Day 28 ± 2 last PR measurement and safety evaluation was performed.  
Results: Are expected for March 2012
